Bank of America keeps USD 41 target for Exelixis stock

Published on 10/27/2026 at 18:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results arrive October 29, 2026. Exelixis stock costs EUR 58.53 on October 27, 2026, plus 2.47 percent versus the Xetra close.

Bank of America maintains Sell view

Bank of America Securities maintained a USD 41.00 target and Sell rating on October 10, 2026.
Second-quarter revenue reached USD 628.69 million, up 10.60 percent year over year.
Exelixis stock costs EUR 58.53 at Lang & Schwarz on October 27, 2026 at 6:43 p.m. CET, 2.47 percent above the Xetra close of October 26, 2026.
Third-quarter results are scheduled for October 29, 2026.

EXEL, US30161Q1040, Illustration mit AI erstellt.

Bank of America Securities maintained its Sell rating and USD 41.00 price target for Exelixis (US30161Q1040) on October 10, 2026, according to The Globe and Mail. The target sits 37.14 percent below Exelixis' USD 65.22 Nasdaq price at 1:48 p.m. ET on October 27, 2026. In Germany, the stock was at EUR 58.53 at Lang & Schwarz on October 27, 2026 at 6:43 p.m. CET, 2.47 percent above the Xetra close of October 26, 2026 at EUR 57.12.

Results arrive October 29

Exelixis will publish third-quarter 2026 financial results after the US market close on October 29, 2026. The company announced the date on October 15, 2026, in an Exelixis release. Management is scheduled to discuss the figures at 5:00 p.m. ET, giving investors a near-term event for testing whether the rally can support a higher valuation.

Revenue reached USD 628.69 million

For the second quarter ended July 3, 2026, Exelixis reported revenue of USD 628.69 million, up 10.60 percent from USD 568.26 million a year earlier. Net income rose to USD 212.05 million from USD 184.85 million, a 14.71 percent increase. These figures were reported by Simply Wall St.

Price sits above the close

The euro quotation is above the October 26 Xetra close, while the US listing remained below its 52-week high of USD 65.59. Exelixis' market capitalization was USD 16.4 billion on October 27, 2026, and its trailing P/E ratio was 20.45. Trading volume stood at 558,499 shares at 1:48 p.m. ET.

Valuation and dates matter

The USD 41.00 Bank of America target contrasts with the USD 65.22 Nasdaq price, placing the target 37.14 percent below the stock. The difference makes the October 29 results particularly relevant: the report can add operating evidence to a valuation debate already reflected in the analyst stance and the current price.

Market position in brief

Exelixis operates in biotechnology and focuses on oncology medicines, including CABOMETYX and pipeline programs such as zanzalintinib. The company's second-quarter revenue and net income figures provide the latest reported operating comparison, while the scheduled third-quarter release supplies the next dated information point.

Stock trades after the Xetra close

Exelixis stock was trading at EUR 58.53 at Lang & Schwarz on October 27, 2026 at 6:43 p.m. CET, up 2.47 percent versus the Xetra close of October 26, 2026 at EUR 57.12. The further course of trading is shown by the continuously updated real-time quote of Exelixis stock.